Nautilus Biotechnology (NAUT) Q3 2026 Earnings Call: Voyager Launch Roadmap and Cash Runway
Source Tradingkey
Key Takeaways
- Nautilus Biotechnology reported Q3 2026 revenue of $0.2 million from Early Access services and grant funding, reflecting its early commercial stage ahead of the Voyager platform launch.
- Net loss widened to $15.6 million, or $0.12 per share, from $13.6 million, or $0.11 per share, a year earlier. Operating expenses increased 10% to $16.9 million.
- Cash, cash equivalents and investments ended the quarter at $114.3 million. Management expects the current financial plan to provide a cash runway into Q1 2028.
- The company now expects total 2026 revenue to exceed its previous outlook of approximately $0.5 million. Q4 revenue is expected to grow sequentially even without contributions from the ARPA-H-funded SEEDS program.
- Nautilus plans to open Voyager platform preorders in early 2027 and begin instrument shipments in mid-2027. Tau, AKT1 and a second oncology assay are expected to be generally available alongside shipments.
- The company remains focused on developing 20 proteoform assays by mid-2028. It may raise additional capital between now and mid-2027 to expand its assay portfolio, platform capabilities and commercial team.
Core Financial Data
| Metric | Q3 2026 | Comparison / Commentary |
|---|---|---|
| Revenue | $0.2 million | Early Access service revenue and Michael J. Fox Foundation grant revenue |
| Operating expenses | $16.9 million | Up approximately 10% from $15.5 million in Q3 2025 |
| R&D expenses | $10.2 million | Up approximately 6% from $9.6 million, mainly due to personnel, laboratory and professional services costs |
| SG&A expenses | $6.8 million | Up approximately 15% from $5.9 million, driven by legal, marketing and personnel costs |
| Net loss | $15.6 million | Compared with $13.6 million in Q3 2025 |
| Net loss per share | $0.12 | Compared with $0.11 in Q3 2025 |
| Cash, cash equivalents and investments | $114.3 million | Down from $129.2 million at the end of Q2 2026 |
| Quarterly cash use | Approximately $14.9 million | Reflected investments in assay development and launch preparation |
Business and Operating Performance
Disclaimer: For information purposes only. Past performance is not indicative of future results.
Recommended Articles
Big tech earnings arrive this week, with Microsoft, Alphabet, and Amazon all releasing quarterly reports.In their latest quarters, Google Cloud grew 82%, Azure 42%, and Amazon Web Services (AWS) 37%,
Fed decision, US inflation and Middle East tensions take centre stage. Explore the US dollar, gold and AUD/USD outlook for Australian traders.
Nasdaq rises 0.82% as Anthropic files for IPO, gold reclaims $4,000 and oil falls. Explore Australia's market outlook ahead of the Fed decision.
South Korea’s KOSPI rose 4.53% from Monday’s close to 5,717.30 on Tuesday morning. The jump made the Korea Exchange pause program buying for five minutes, its second brake in six days.The first brake,
Bitcoin is fighting to hold $80,000 after three consecutive weeks of losses. The broader crypto market remains under pressure as weak investor confidence and volatility in global stocks weigh on price
